Home › Modalities › Protein

Protein (81 companies)

Ticker	Company	Therapeutic areas	Programs	Lead stage	Programs
ABSI	Absci	DermatologyGI/Hepatology+1	6	Phase 1	6
ACIU	AC Immune	Neurology Rare	4	Phase 3	10
ACRS	Aclaris Therapeutics	DermatologyGI/Hepatology+1 Rare	4	Phase 2	8
ABOS	Acumen Pharmaceuticals	Neurology	4	Phase 2	4
ADAG	Adagene	Oncology	10	Phase 2	10
ADCT	ADC Therapeutics	Oncology	5	Approved	5
ADMA	Adma Biologics	ImmunologyInfectious Disease Rare	4	Approved	4
AGMB	Agomab Therapeutics	ImmunologyRespiratory Rare	2	Phase 2	4
AKBA	Akebia Therapeutics	HematologyOphthalmology+2 Rare	3	Approved	10
ANAB	AnaptysBio	DermatologyGI/Hepatology+2 Rare	6	Approved	6
ANIX	Anixa Biosciences	Oncology	2	Phase 1	3
ANNX	Annexon	HematologyNeurology+2 Rare	5	Phase 3	6
APGE	Apogee Therapeutics	DermatologyGI/Hepatology+1 Rare	9	Phase 2	9
APVO	Aptevo Therapeutics	Oncology	8	Phase 1	8
RCUS	Arcus Biosciences	DermatologyImmunology+1	2	Phase 3	6
BEAM	Beam Therapeutics	HematologyMetabolic+1 Rare	1	Phase 2	6
BCAX	Bicara Therapeutics	Oncology	4	Phase 2	4
BCTX	BriaCell Therapeutics	Oncology	1	Phase 3	7
CAPR	Capricor Therapeutics	Infectious DiseaseNeurology Rare	1	NDA Submitted	2
CLDX	Celldex Therapeutics	DermatologyImmunology+1	7	Phase 3	7
CLYM	Climb Bio	HematologyImmunology+1 Rare	6	Phase 2	7
CHRS	Coherus Oncology	Oncology	3	Approved	3
CMPX	Compass Therapeutics	Oncology	9	Phase 2	9
CGEN	Compugen	Oncology	7	Phase 3	7
CNTB	Connect Biopharma	Respiratory	4	Phase 2	4
CRVS	Corvus Pharmaceuticals	DermatologyOncology	1	Phase 3	4
CBIO	Crescent Biopharma	Oncology	10	Phase 2	10
CUE	Cue Biopharma	ImmunologyOncology	6	Phase 2	6
CGEM	Cullinan Therapeutics	HematologyImmunology+2 Rare	9	NDA Submitted	10
CYDY	CytoDyn	NeurologyOncology	3	Phase 2	3
CTMX	CytomX Therapeutics	Oncology	6	Phase 1	6
DBVT	DBV Technologies	Immunology	2	NDA Submitted	2
DYN	Dyne Therapeutics	MetabolicNeurology Rare	1	NDA Submitted	10
ELDN	Eledon Pharmaceuticals	ImmunologyNeurology Rare	2	Phase 2	2
ERAS	Erasca	Oncology	1	Phase 1	3
ETON	Eton Pharmaceuticals	GI/HepatologyInfectious Disease+2 Rare	1	Approved	14
EVMN	Evommune	DermatologyImmunology+1	3	Phase 2	6
EXEL	Exelixis	CardiovascularOncology	5	Approved	22
FBRX	Forte Biosciences	DermatologyGI/Hepatology	3	Phase 2	3
FBIO	Fortress Biotech	DermatologyHematology+2 Rare	3	Approved	12
IMTX	Immatics	Oncology	6	Phase 2	8
IBRX	ImmunityBio	Infectious DiseaseOncology	6	Approved	16
IMNM	Immunome	Oncology Rare	7	NDA Submitted	9
IMVT	Immunovant	ImmunologyNeurology Rare	6	Phase 3	6
INAB	IN8bio	ImmunologyOncology	1	Phase 2	6
INSM	Insmed	CardiovascularDermatology+2 Rare	1	Approved	9
JBIO	Jade Biosciences	ImmunologyRenal Rare	4	Phase 2	4
JANX	Janux Therapeutics	Oncology	2	Phase 1	3
KAPA	Kairos Pharma	Oncology	4	Phase 2	9
KOD	Kodiak Sciences	Ophthalmology	8	Phase 3	8
LRMR	Larimar Therapeutics	Neurology Rare	1	NDA Submitted	1
MDNAF	Medicenna Therapeutics	Oncology	9	Phase 2	9
MLTX	MoonLake Immunotherapeutics	DermatologyImmunology Rare	4	Phase 3	4
NKTR	Nektar Therapeutics	DermatologyImmunology+2	11	Phase 3	11
NBP	NovaBridge Biosciences	OncologyOphthalmology	6	Phase 2	6
OCGN	Ocugen	Infectious DiseaseOphthalmology Rare	3	Phase 3	12
OCS	Oculis Holding	NeurologyOphthalmology Rare	1	Phase 3	4
OMER	Omeros	HematologyNeurology+2 Rare	4	Approved	6
ORKA	Oruka Therapeutics	DermatologyImmunology Rare	6	Phase 2	7
OTLK	Outlook Therapeutics	Ophthalmology	3	Approved	3
PMN	ProMIS Neurosciences	Neurology Rare	6	Phase 1	6
SABS	SAB Biotherapeutics	Metabolic	1	Phase 2	1
SPRB	Spruce Biosciences	Metabolic Rare	2	Preclinical	2
SYRE	Spyre Therapeutics	DermatologyImmunology Rare	13	Phase 2	13
SMMT	Summit Therapeutics	Oncology	4	NDA Submitted	4
STRO	Sutro Biopharma	Oncology	4	Phase 1	4
TECX	Tectonic Therapeutic	Cardiovascular Rare	3	Phase 2	3
TGTX	Tg Therapeutics	Neurology Rare	5	Approved	6
TVTX	Travere Therapeutics	MetabolicRenal Rare	1	Approved	7
RARE	Ultragenyx Pharmaceutical	CardiovascularGI/Hepatology+2 Rare	5	Approved	12
VNDA	Vanda Pharmaceuticals	CardiovascularDermatology+6 Rare	1	Approved	29
PCVX	Vaxcyte	Infectious Disease	6	Phase 3	6
VERA	Vera Therapeutics	Infectious DiseaseRenal Rare	6	Approved	6
VIR	Vir Biotechnology	Infectious DiseaseOncology Rare	10	Phase 3	10
VRDN	Viridian Therapeutics	ImmunologyOphthalmology	5	Approved	5
VOR	Vor Biopharma	ImmunologyNeurology Rare	2	Phase 3	2
VYGR	Voyager Therapeutics	MetabolicNeurology Rare	1	Phase 1	9
XNCR	Xencor	HematologyImmunology+4 Rare	36	Approved	36
ZBIO	Zenas BioPharma	DermatologyImmunology+2 Rare	7	NDA Submitted	11
ZURA	Zura Bio	DermatologyImmunology Rare	5	Phase 2	5
ZYME	Zymeworks	OncologyRespiratory	11	Approved	11